Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 June 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Severe hepatotoxicity during combination antiretroviral treatment

Liver damage may be caused by immune reconstitution and related exacerbation of viral hepatitis during antiretroviral therapy, find researchers in the March issue of the Journal of Acquired Immune Deficiency Syndromes.

News image

fiogf49gjkf04

In this study, researchers from Italy assessed incidence, risk factors, histology, and outcome of severe hepatotoxicity (SH) during antiretroviral treatment (ART).

The team included 755 HIV-seropositive patients prescribed new ART in the study.

Liver function tests were assessed at baseline, after 1 month, and every 4 months thereafter.

The team performed liver biopsies in the case of SH.

Liver damage was invariably observed in patients with chronic viral hepatitis.
Journal of Acquired Immune Deficiency Syndromes

The research team observed 26 cases of SH, with an incidence of 4% person-years. However, liver failure was rarely seen.

The team found that liver damage was invariably observed in patients with chronic viral hepatitis.

Liver histology showed exacerbation of viral hepatitis in all 16 patients for whom a liver biopsy was available at the time of SH.

They found a direct correlation between alanine aminotransferase increase and increase in CD4+ T-cell count in patients with SH.

Death occurred during follow-up in 7 of the 26 patients with SH. All showed liver failure and a baseline CD4+ count less than 200 cells/mm3.

In addition, the researchers observed relapse of SH following recommencement of ART, in 7 of 17 patients. However, 5 of these 7 patients did not show further SH relapse after treatment with interferon.

Dr Massimo Puoti’s team concluded, “This study provides estimates of SH and liver failure…where hepatitis C virus coinfection is highly prevalent and provides indications that liver damage may be caused by immune reconstitution and related exacerbation of viral hepatitis”.

“A strict follow-up for hepatotoxicity is mandatory when ART is initiated in patients with < 200 CD4+ T cells/mm3.”

“Antihepatitis pre- or comedication could be an effective preventive or curative measure.”

J Acquir Immune Defic Syndr 2003; 32(3): 259-67
12 March 2003

Go to top of page Email this page Email this page to a colleague

 23 June 2017 
Treatment for KRAS wild-type advanced colorectal cancer
 23 June 2017 
Epidemiology of Hep E
 23 June 2017 
Predictive model for clinical course of Crohn's disease
 22 June 2017 
Vonoprazan-based triple therapy on H. pylori eradication
 22 June 2017 
Adolescent transition in IBD
 22 June 2017 
Patient understanding of biologic therapy in IBD
 21 June 2017 
Hydrolyzed wheat flour improves immunogenicity in celiac disease
 21 June 2017 
Statins in chronic Hep C
 21 June 2017 
Racial disparities in colorectal cancer
 20 June 2017 
Therapies in chronic pancreatitis
 20 June 2017 
Genetic analyses for malignancy detection in biliary strictures
 20 June 2017 
Viral-associated esophagus cancers
 19 June 2017 
Global prevalence of IBS in adults
 19 June 2017 
Clinical improvement in mild acute pancreatitis
 19 June 2017 
Repeat biopsy and celiac disease outcomes 
 16 June 2017 
Exercise-induced GI syndrome—implications for intestinal disease
 16 June 2017 
HCV among reproductive-aged women and children in the USA
 16 June 2017 
Adverse events after outpatient colonoscopy
 15 June 2017 
Pioglitazone for NASH
 15 June 2017 
Urinary adverse events after rectal cancer treatment
 15 June 2017 
Treatment of eosinophilic esophagitis
 14 June 2017 
Genetics of familial colorectal cancer
 14 June 2017 
Abdominal ultrasound in blunt torso trauma
 14 June 2017 
Acute kidney injury in Hep C and sofosbuvir-based regimens
 13 June 2017 
Serrated polyps in the colon and rectum
 13 June 2017 
Colorectal cancer during pregnancy
 13 June 2017 
Biomarker for penetrating Crohn's
 12 June 2017 
Course of primary sclerosing cholangitis
 12 June 2017 
Quality of life in end-stage liver disease
 12 June 2017 
Clinical remission in patients with Crohn's disease
 09 June 2017 
Socioeconomic influences on H. pylori gastritis
 09 June 2017 
Celiac disease in Ireland
 09 June 2017 
Consultants do not follow up on GI tests they recommend
 08 June 2017 
Genetics and the gut microbiota and metabolic syndrome
 08 June 2017 
Antireflux surgery in extraesophageal reflux
 08 June 2017 
Breath testing in gastrointestinal disorders
 07 June 2017 
Multidisciplinary care and liver cancer
 07 June 2017 
Model for excluding NAFLD
 07 June 2017 
Hospital readmission in IBD
 06 June 2017 
Dietary patterns and colorectal cancer risk
 06 June 2017 
Direct-acting antiviral agents for HCV
 06 June 2017 
Medical therapies for stricturing Crohn’s
 05 June 2017 
Celiac disease prevalence in the USA
 05 June 2017 
Hospital-acquired conditions in Crohn’s disease
 05 June 2017 
Depression and IBD
 02 June 2017 
Menopausal hormone therapy and fecal incontinence
 02 June 2017 
Narcotic and corticosteroid prescriptions in IBD
 02 June 2017 
Treating anemia after gastrectomy
 01 June 2017 
Infliximab and cancer in pediatric IBD
 01 June 2017 
Health insurance policies in IBD
 01 June 2017 
Endoscopic quality improvement program for polyp detection
 31 May 2017 
Probiotics and Clostridium difficile infection
 31 May 2017 
Post-procedural adverse events after colonoscopy
 31 May 2017 
Clinical decision-making in severe alcoholic hepatitis
 30 May 2017 
Waist belts and reflux
 30 May 2017 
Colorectal cancer increases in developed and developing regions
 30 May 2017 
Antidepressants and bleeding in peptic ulcers
 26 May 2017 
Accreditation program for rectal cancer
 26 May 2017 
Risk of lower GI bleeds with aspirin
 26 May 2017 
Adverse events after outpatient colonoscopy in high-risk patients

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us